Drug intelligence / Profile preview

STC2011-f001

Development stage: Preclinical
Lead developer: STC Life
Modality: Small Molecules

Overview

STC2011-f001 is a preclinical small molecule drug candidate developed by STC Life for the treatment of obesity. Derived from herbal extracts, the agent is designed to act on adipocytes and preadipocytes, likely by modulating adipocyte differentiation (adipogenesis) or metabolic function. It is currently being evaluated in early-stage research at STC Life's New Drug Research & Development Center. The specific molecular mechanism of action has not been disclosed, but the candidate represents a natural material-based approach to metabolic disease management.

Other names: STC Life obesity herbal extract

Beyond the preview

Go deeper on STC2011-f001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC2011-f001.

Explore the full profile